Stock PCVX VAXCYTE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Market Closed - Nasdaq
Other stock markets
 01:30:00 14/09/2024 am IST 		5-day change 1st Jan Change
116.00 USD +1.64% Intraday chart for Vaxcyte, Inc. +3.96% +84.71%
10/09 Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree... Our Logo
10/09 Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating MT

Evolution of the Average Target: Vaxcyte, Inc.

Evolution of the Target Price: Vaxcyte, Inc.

Changes in Analyst Recommendations: Vaxcyte, Inc.

5e802f70a73adaf536aac16baf0c21.PQnEcU2pDda6HnmgTR4r2eNXCMkwBnOLBl6By5G9q1M.fE6sQniaXLTZcCPFNX94jLAvRPteQiW8WRy5maDtwRpbXrMLBtlYheVoPA~889ff8a204c0d2a2e94b56562ebe7aa1

Analysts' recommendations: Vaxcyte, Inc.

Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree... Our Logo
Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating MT
Vaxcyte Insider Sold Shares Worth $649,325, According to a Recent SEC Filing MT
Vaxcyte Insider Sold Shares Worth $425,000, According to a Recent SEC Filing MT
Vaxcyte Insider Sold Shares Worth $599,909, According to a Recent SEC Filing MT
Vaxcyte Insider Sold Shares Worth $928,845, According to a Recent SEC Filing MT
Vaxcyte Insider Sold Shares Worth $552,144, According to a Recent SEC Filing MT
Mizuho Adjusts Price Target on Vaxcyte to $113 From $69, Maintains Buy Rating MT
Needham Raises Price Target on Vaxcyte to $95 From $73, Maintains Buy Rating MT
Mizuho Initiates Vaxcyte With Buy Rating, Price Target is $69 MT
TD Cowen Starts Vaxcyte at Outperform MT
BofA Securities Adjusts Price Target on Vaxcyte to $68 From $63, Keeps Buy Rating MT
Guggenheim Adjusts Price Target on Vaxcyte to $65 From $66, Maintains Buy Rating MT
Needham Adjusts Price Target on Vaxcyte to $58 From $52, Maintains Buy Rating MT
SVB Securities Initiates Vaxcyte With Outperform Rating, Sets Price Target at $60 MT
Guggenheim Initiates Vaxcyte at Buy With $66 Price Target MT
BTIG Starts Vaxcyte at Buy With $69 Price Target MT
More recommendations

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Analyst Opinion 4m Revision of opinion Divergence of analysts' opinions Divergence of Target Price Ecart obj. / dr
VAXCYTE, INC. Stock Vaxcyte, Inc.
+25.00%
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+5.04%
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.77%
ARGENX SE Stock argenx SE
+4.66%
BIONTECH SE Stock BioNTech SE
-10.73%
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
-23.10%
BEIGENE, LTD. Stock BeiGene, Ltd.
+37.52%
GENMAB A/S Stock Genmab A/S
+33.89%
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
+47.62%
INSMED INCORPORATED Stock Insmed Incorporated
+17.20%
Average +13.79%
Weighted average by Cap. +6.58%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
116.00USD
Average target price
145.00USD
Spread / Average Target
+25.00%
High Price Target
163.00USD
Spread / Highest target
+40.52%
Low Price Target
129.00USD
Spread / Lowest Target
+11.21%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Mizuho Securities
Needham & Co.
TD Cowen
BofA Securities
Guggenheim
SVB Securities LLC
BTIG
Profit revisions
Estimate revisions

Quarterly earnings, Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. PCVX Stock
  4. Consensus Vaxcyte, Inc.
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities. Last hours!
BENEFIT NOW
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition